Articles | Volume 10, issue 4
https://doi.org/10.5194/jbji-10-255-2025
https://doi.org/10.5194/jbji-10-255-2025
Original full-length article
 | 
30 Jul 2025
Original full-length article |  | 30 Jul 2025

Proactive Therapeutic Drug MONiToring to Guide Suppressive Antibiotic Therapy with DALBAvaNcin ( > 12 weeks) in Osteoarticular Infections (MONTALBANO)

Chiara Mariani, Matteo Passerini, Lucia Galli, Alice Covizzi, Marta Colaneri, Martina Offer, Margherita Faenzi, Stefania Merli, Simona Landonio, Marta Fusi, Alberto Dolci, Andrea Gori, and Dario Cattaneo

Related authors

Cutibacterium acnes in spine tissue: characteristics and outcomes of non-hardware-associated vertebral osteomyelitis
Matteo Passerini, Julian Maamari, Don Bambino Geno Tai, Robin Patel, Aaron J. Tande, Zelalem Temesgen, and Elie F. Berbari
J. Bone Joint Infect., 8, 143–149, https://doi.org/10.5194/jbji-8-143-2023,https://doi.org/10.5194/jbji-8-143-2023, 2023
Short summary
Early switch to oral antibiotic therapy for the treatment of patients with bacterial native vertebral osteomyelitis: a quaternary center experience, systematic review, and meta-analysis
Matteo Passerini, Julian Maamari, Tarek Nayfeh, Leslie C. Hassett, Aaron J. Tande, Mohammad H. Murad, Zelalem Temesgen, and Elie F. Berbari
J. Bone Joint Infect., 7, 249–257, https://doi.org/10.5194/jbji-7-249-2022,https://doi.org/10.5194/jbji-7-249-2022, 2022
Short summary

Related subject area

Subject: Anti-bacterial agents | Topic: Systemic administration
Efficacy of rezafungin in a case of Candida spondylodiskitis
Marin Lahouati, Claire Tinévez, Frédéric Gabriel, Fabien Xuereb, Maxime Lefranc, and Frédéric-Antoine Dauchy
J. Bone Joint Infect., 9, 213–215, https://doi.org/10.5194/jbji-9-213-2024,https://doi.org/10.5194/jbji-9-213-2024, 2024
Short summary

Cited articles

Azamgarhi, T., Warren, S., Scobie, A., Karunaharan, N., Perez-Sanchez, C., Houghton, R., Hassan, S., Lourtet-Hascoët, J., Kershaw, H., Sendi, P., and Saeed, K.: Dalbavancin to facilitate early discharge in the treatment of complex musculoskeletal infections: a multi-centre real-life application, J. Bone Joint Infect., 10, 93–100, https://doi.org/10.5194/jbji-10-93-2025, 2025. 
Bork, J. T., Heil, E. L., Berry, S., Lopes, E., Davé, R., Gilliam, B. L., and Amoroso, A.: Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections, Infect. Dis. Ther., 8, 171–184, https://doi.org/10.1007/s40121-019-0247-0, 2019. 
Boucher, H. W., Wilcox, M., Talbot, G. H., Puttagunta, S., Das, A. F., and Dunne, M. W.: Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection, New Engl. J. Med., 370, 2169–2179, https://doi.org/10.1056/nejmoa1310480, 2014. 
Buckwalter, M. and Dowell, J. A.: Population Pharmacokinetic Analysis of Dalbavancin, a Novel Lipoglycopeptide, J. Clin. Pharmacol., 45, 1279–1287, https://doi.org/10.1177/0091270005280378, 2005. 
Cattaneo, D., Fusi, M., Colaneri, M., Fusetti, C., Genovese, C., Giorgi, R., Matone, M., Merli, S., Petri, F., and Gori, A.: Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience, Antibiotics, 13, 20, https://doi.org/10.3390/antibiotics13010020, 2023. 
Download
Short summary
Bone and joint infections often require prolonged antibiotic treatments over 12 weeks. Dalbavancin, an intravenous antibiotic given at spaced intervals, offers a promising option. Our study developed a method to optimize dosing schedules using two blood tests to measure drug levels. This ensures effective treatment while avoiding excessive accumulation. These findings suggest dalbavancin is a safe, effective choice for managing long-term infections.
Share